SCHEMBL282456

SCHEMBL282456

CCOC(=O)/C=C/c1cc(C)c(Oc2ccc(OC)c(C(C)C)c2)c(C)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.50
MAOB P27338 1/20 0.49
ESR1 P03372 2/20 0.48
THRB P10828 3/20 0.47
RORC P51449 2/20 0.47
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
CYP3A4 P08684 1/20 0.43
THRA P10827 1/20 0.43
BCHE P06276 2/20 0.42
ACHE P22303 2/20 0.42
KMT2A Q03164 1/20 0.42
ALOX5 P09917 1/20 0.42
TTR P02766 1/20 0.42
DPP4 P27487 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7073301 0.90 THRB (0.48) FDPSMAOBESR1THRBRORC
SCHEMBL7073304 0.90 THRB (0.48) FDPSMAOBESR1THRBRORC
SCHEMBL283056 0.81 THRB (0.54) THRBRORCTHRA
SCHEMBL282495 0.80 THRB (0.43) THRBRORCTHRACA12CA1
SCHEMBL282394 0.79 THRB (0.50) THRBRORCALDH1A1THRA
SCHEMBL3222511 0.79 THRB (0.47) THRBRORCTHRA
SCHEMBL8893208 0.79 THRB (0.47) THRBRORCTHRA
SCHEMBL8798523 0.78 THRB (0.54) THRBRORCTHRA
SCHEMBL8892324 0.77 THRB (0.48) THRBRORCTHRA
SCHEMBL282165 0.76 THRB (0.53) THRBRORCTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1689383-B1 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS INC (US) 2012-10-31 EP disclosed
EP-2428516-A1 Novel phosphorus-containing thyromimetics Metabasis Therapeutics, Inc. (US) 2012-03-14 EP disclosed
US-7829552-B2 Phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. (US) 2010-11-09 US disclosed
US-20100081634-A1 Novel Phosphorus-Containing Thyromimetics METABASIS THERAPEUTICS, INC. (US) 2010-04-01 US disclosed
US-20090118236-A1 Novel Phosphorus-Containing Thyromimetics CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2009-05-07 US disclosed
US-7514419-B2 Phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. (US) 2009-04-07 US disclosed
US-20090028925-A1 Novel Phosphinic Acid-Containing Thyromimetics METABASIS THERAPEUTICS, INC. 2009-01-29 US disclosed
US-20060046980-A1 Novel phosphorus-containing thyromimetics METABASIS THERAPEUTICS, INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081634-A1 Novel Phosphorus-Containing Thyromimetics PYGL, THRA, THOP1 FDPS 524/4885MAOB 3749/4885ESR1 1256/4885
US-20060046980-A1 Novel phosphorus-containing thyromimetics PYGL, THRA, THOP1 FDPS 524/4885MAOB 3749/4885ESR1 1256/4885
US-20090118236-A1 Novel Phosphorus-Containing Thyromimetics THRA, PYGL, THRB FDPS 872/4885MAOB 4237/4885ESR1 1422/4885
US-20090028925-A1 Novel Phosphinic Acid-Containing Thyromimetics PYGL, PHOSPHO1, LIPE FDPS 890/4885MAOB 3524/4885ESR1 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.